laboratorio de especialidades bolivar · 250 71.224 7.9 0.44 4.63 53 67.904 2.5 0.29 4.42 your...
TRANSCRIPT
Laboratorio de Especialidades Bolivar
55 Diamond Road
CRUMLIN BT29 4QY
Tel: +44 (0)28 9445 4399
Fax: +44 (0)28 9445 4398
Randox Laboratories Limited
ABC
LABORATORY REF. NO. 18042/N
Email: [email protected] Page 1
Authorised by: Stephen Doherty, RIQAS Manager Issue No: 1 Issue Date: 29/03/2017
IMMUNOASSAY
RIQAS
CYCLE 46 SAMPLE 7
Explanation of codes used in this report
R - Results removed due to reconstitution error
N - No result returned
C - Result corrected
All Methods
Abbott Architect
N Mean CV% U SDPA
250 71.224 7.9 0.44 4.63
53 67.904 2.5 0.29 4.42
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
70.140 0.51
0.24
67.904 101
99
AFP, ng/ml
%DEV
RM%DEV
3.3
1.6
m
< 56.45 60.67 64.89 69.11 73.33 77.55 81.77 85.99 >
0
5
10
15
20
25
30
35
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
63.0
49
M
67.9
66
M
247.7
44
M
12.9
02
M
154.4
47
M
38.4
38
M
131.1
51
M
245.0
72
M
133.0
37
M
13.0
44
M
153.9
89
M
38.7
05
M
68.4
49
M
122.8
57
M
67.9
09
M
147.6
37
M
13.3
60
M
41.2
43
M
229.0
62
M
67.9
04
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
21.9%
10.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 71 72.715 3.5 0.38
Abbott Architect 53 67.904 2.5 0.29
Roche Cobas 4000/e411 31 73.727 8.7 1.44
Siemens Centaur XP/XPT/Classic 22 81.675 4.7 1.02
Beckman DxI 600 /800 19 65.416 4.3 0.81
Siemens/DPC Immulite 2000/2500 10 62.590 6.4 1.58
bioMerieux, Vidas/Mini Vidas 9 58.479 10.5 2.56
Ortho Vitros 3600/5600/ECi 8 78.361 8.2 2.84
Roche Elecsys 8 75.562 4.2 1.39
Roche Modular E170 4 74.201 4.3 1.99
Siemens/DPC Immulite 1000 3 68.273 5.8 2.87
DiaSorin, Liaison 3 78.257 16.3 9.20
Beckman Access/LXi725 3 69.426 2.0 1.01
SNIBE Maglumi analysers 2 59.922 4.6 2.46
Siemens Centaur CP 2 76.718 14.2 9.60
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 50 100 150 200 250
Concentration
Page 2Issue No: 1 Issue Date: 29/03/2017
Exc.
23
5
All Methods
Abbott Architect
N Mean CV% U SDPA
285 109.005 15.6 1.26 6.43
61 141.816 4.6 1.03 8.36
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
147.200 0.64
0.29
141.816 91
101
CA 125, U/ml
%DEV
RM%DEV
3.8
1.8
m
< 64.46 77.19 89.91 102.64 115.36 128.09 140.81 153.54 >
0
10
20
30
40
50
60
70
80
U/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
136.6
00
M
144.4
09
M
283.0
50
M
28.0
27
M
204.4
15
M
81.7
33
M
156.9
00
M
274.4
82
M
156.7
31
M
27.7
25
M
202.5
14
M
81.1
03
M
142.2
51
M
165.8
64
M
141.5
81
M
216.6
96
M
29.6
03
M
88.3
03
M
300.3
98
M
141.8
16
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 9.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
35.4%
9.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 75 104.166 3.1 0.47
Abbott Architect 61 141.816 4.6 1.03
Roche Cobas 4000/e411 45 107.885 4.4 0.88
Siemens Centaur XP/XPT/Classic, CA125 II 25 100.082 6.3 1.58
Beckman DxI 600 /800 21 78.405 5.6 1.20
bioMerieux VIDAS 15 103.645 4.5 1.50
Ortho Vitros 3600/5600/ECi 10 99.979 4.2 1.64
Siemens/DPC Immulite 2000/2500 8 97.776 3.1 1.33
Roche Elecsys 7 104.671 10.0 4.97
Roche Modular E170 5 106.158 6.0 3.59
SNIBE Maglumi analysers 4 116.228 23.0 16.70
Siemens/DPC Immulite 1000 2 110.500 7.0 6.87
DiaSorin Liaison 3 135.000 11.9 11.61
Brahms Kryptor 2 37.250 8.5 2.81
Beckman Access/LXi725 2 82.550 10.2 7.44
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
10 60 110 160 210 260 310
Concentration
Page 3Issue No: 1 Issue Date: 29/03/2017
Exc.
20
4
All Methods
Abbott Architect
N Mean CV% U SDPA
178 49.638 8.4 0.39 3.26
44 53.698 5.6 0.56 3.53
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
55.100 0.40
-0.07
53.698 112
109
CA 15-3, U/ml
%DEV
RM%DEV
2.6
-0.4
m
< 38.75 41.86 44.97 48.08 51.19 54.30 57.40 60.51 >
0
5
10
15
20
25
30
35
U/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
38.6
13
M
44.3
89
M
95.9
31
M
21.9
91
M
68.3
70
M
33.3
28
M
58.8
89
M
95.5
32
M
58.5
02
M
22.6
57
M
69.5
75
M
33.9
15
M
45.5
93
M
66.3
83
M
53.6
53
M
82.4
78
M
23.0
25
M
38.9
34
M
110.7
11
M
53.6
98
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.8%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
20.8%
10.80%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 54 48.613 4.2 0.34
Abbott Architect 44 53.698 5.6 0.56
Roche Cobas 4000/e411 27 48.620 5.4 0.63
Siemens Centaur XP/XPT/Classic 20 46.380 7.1 0.92
Beckman DxI 600 /800 12 27.452 5.5 0.55
Roche Elecsys 6 48.343 11.5 2.83
Ortho Vitros 3600/5600/ECi 5 47.436 2.3 0.60
BioMerieux VIDAS 4 43.695 4.9 1.35
Siemens/DPC Immulite 2000/2500 4 60.763 2.3 0.86
Roche Modular E170 4 49.975 9.8 3.05
Brahms Kryptor 2 51.500 1.4 0.62
Siemens/DPC Immulite 1000 2 75.400 6.4 4.25
DiaSorin, Liaison 2 53.700 9.7 4.62
SNIBE Maglumi analysers 1 36.500 0.0 0.00
TOSOH 2 53.880 19.1 9.10
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
10 30 50 70 90 110
Concentration
Page 4Issue No: 1 Issue Date: 29/03/2017
Exc.
23
3
All Methods
Abbott Architect
N Mean CV% U SDPA
227 181.941 115.4 17.43 21.77a
22 705.827 5.2 9.75 50.64
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
732.280 0.52
0.11
705.827 100
90
CA 19-9, U/ml
%DEV
RM%DEV
3.7
0.8
m
< 50.75 152.25 253.76 355.27 456.77 558.28 659.78 761.29 >
0
20
40
60
80
100
120
140
U/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
230.3
51
M
737.9
80
M
1820.8
93
M
197.7
67
M
1105.0
45
M
436.4
73
M
896.7
15
M
1833.6
68
M
903.9
31
M
196.4
24
M
1093.5
70
M
443.2
46
M
727.0
47
M
936.5
06
M
707.9
19
M
1158.3
98
M
207.7
66
M
473.5
48
M
1842.5
75
M
705.8
27
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 11.8%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
46.03%
11.80%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 66 61.053 3.9 0.37
Roche Cobas 4000/e411 31 64.939 5.7 0.83
Abbott Architect 22 705.827 5.2 9.75
Abbott Architect XR/ XR2 kit 23 716.360 6.2 11.55
Siemens Centaur XP/XPT/Classic 19 248.663 5.8 4.12
Beckman DxI 600 /800 18 90.669 5.0 1.33
bioMerieux, VIDAS 13 163.782 6.9 3.89
Siemens/DPC Immulite 2000/2500 9 99.094 10.3 4.24
Roche Elecsys 6 66.468 8.0 2.70
Ortho Vitros 3600/5600/ECi 5 170.000 2.3 2.17
Roche Modular E170 4 62.110 1.8 0.70
Siemens Centaur CP 2 214.475 15.7 29.72
Siemens/DPC Immulite 1000 2 111.000 7.6 7.50
DiaSorin, Liaison 2 141.550 21.9 27.44
Beckman Access/LXi725 2 107.350 10.3 9.81
SNIBE Maglumi analysers 1 69.790 0.0 0.00
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 200 400 600 800 1000 1200 1400 1600 1800
Concentration
Page 5Issue No: 1 Issue Date: 29/03/2017
Exc.
19
4
All Methods
Abbott Architect
N Mean CV% U SDPA
309 26.233 12.0 0.22 1.47
68 30.080 4.6 0.21 1.68
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
29.960 -0.07
0.11
30.080 120
102
CEA, ng/ml
%DEV
RM%DEV
-0.4
0.6
m
< 17.96 20.32 22.68 25.05 27.41 29.77 32.13 34.50 >
0
10
20
30
40
50
60
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
25.9
58
M
19.4
07
M
59.4
49
M
4.1
60
M
41.4
87
M
14.8
08
M
31.3
04
M
59.0
34
M
31.4
34
M
4.2
21
M
42.2
15
M
14.9
00
M
19.3
41
M
35.8
37
M
29.6
86
M
48.6
40
M
4.4
96
M
17.0
83
M
68.8
37
M
30.0
80
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 9.2%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
24.7%
9.20%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 85 23.896 3.3 0.11
Abbott Architect 68 30.080 4.6 0.21
Roche Cobas 4000/e411 45 24.269 4.9 0.22
Siemens Centaur XP/XPT/Classic 22 29.932 7.2 0.57
Beckman DxI 600 /800 23 24.573 7.2 0.46
bioMerieux, VIDAS 13 26.715 4.5 0.42
Ortho Vitros 3600/5600/ECi 11 28.940 2.4 0.26
Siemens/DPC Immulite 2000/2500 11 39.405 8.0 1.19
Roche Elecsys 7 24.061 6.5 0.74
Roche Modular E170 6 23.277 2.0 0.24
Siemens/DPC Immulite 1000 5 39.720 7.4 1.64
DiaSorin, Liaison 4 23.653 10.4 1.54
Beckman Access/LXi725 4 24.953 7.4 1.15
SNIBE Maglumi analysers 3 26.677 15.0 2.88
Tosoh 3 43.067 8.8 2.74
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 10 20 30 40 50 60 70
Concentration
Page 6Issue No: 1 Issue Date: 29/03/2017
Exc.
23
2
All Methods
Abbott Architect
N Mean CV% U SDPA
270 20.436 10.0 0.16 1.55
47 18.305 3.5 0.12 1.39
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
19.500 0.86
0.86
18.305 78
81
Cortisol, ug/dl
%DEV
RM%DEV
6.5
6.4
m
< 15.07 16.60 18.13 19.66 21.20 22.73 24.26 25.79 >
0
5
10
15
20
25
30
35
40
45
ug/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
19.1
21
M
18.5
58
M
27.9
54
M
7.3
33
M
23.0
42
M
13.8
36
M
18.6
29
M
27.6
07
M
18.4
22
M
7.3
54
M
22.7
40
M
13.5
55
M
18.6
90
M
18.2
12
M
18.3
35
M
22.4
43
M
7.1
28
M
13.7
40
M
27.0
73
M
18.3
05
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 12.5%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
22.8%
12.50%RIQAS
Method N Mean CV% U
Abbott Architect 47 18.305 3.5 0.12
Roche Cobas 6000/8000 Gen II 51 19.877 4.2 0.15
Roche Cobas 4000/e411 30 22.458 11.5 0.59
Siemens Centaur XP/XPT/Classic 23 24.699 6.1 0.39
Beckman DxI 600 /800 25 19.920 4.0 0.20
Siemens/DPC Immulite 2000/2500 19 21.282 4.2 0.26
Roche Cobas 6000/8000 18 21.224 9.5 0.59
Ortho Vitros 3600/5600/ECi 11 19.649 4.1 0.30
Siemens/DPC Immulite 1000 10 21.596 6.8 0.58
Roche Cobas 4000/e411 Gen II 8 21.238 4.6 0.43
Roche Elecsys 6 23.070 6.8 0.80
bioMerieux, VIDAS 4 17.682 13.9 1.54
Roche Modular E170 4 21.641 6.5 0.88
Beckman Access/LXi725 4 20.924 12.1 1.58
CIS, RIA 2 17.755 2.0 0.32
Roche Modular E170 Gen II 2 20.441 4.7 0.85
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 5 10 15 20 25 30
Concentration
Page 7Issue No: 1 Issue Date: 29/03/2017
Exc.
22
8
All Methods
Abbott Architect
N Mean CV% U SDPA
109 549.449 12.0 7.87 42.76
20 519.313 3.2 4.63 40.41
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
551.600 0.80
0.22
519.313 81
101
DHEA-S, ug/dl
%DEV
RM%DEV
6.2
1.8
m
< 376.83 426.15 475.47 524.79 574.10 623.42 672.74 722.05 >
0
2
4
6
8
10
12
14
16
18
20
ug/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
534.2
22
M
498.9
48
M
894.3
78
M
97.2
82
M
703.4
25
M
314.4
42
M
476.0
48
M
892.6
36
M
476.8
37
M
91.7
37
M
709.6
77
M
313.6
41
M
511.2
98
M
413.8
41
M
510.5
94
M
639.1
93
M
111.8
46
M
311.2
74
M
782.3
13
M
519.3
13
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 12.8%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
10.9%
12.80%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 34 606.654 4.3 5.60
Abbott Architect 20 519.313 3.2 4.63
Siemens/DPC Immulite 2000/2500 13 454.114 3.4 5.33
Roche Cobas 4000/e411 12 583.219 3.6 7.54
Siemens/DPC Immulite 1000 5 477.910 10.8 28.84
Siemens Centaur XP/XPT/Classic 4 417.538 10.6 27.77
Roche Elecsys 4 584.033 8.4 30.57
Roche Modular E170 4 568.693 4.6 16.31
Beckman DxI 600 /800 3 430.751 11.2 34.79
DiaSorin, Liaison 1 568.000 0.0 0.00
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
40 140 240 340 440 540 640 740 840 940
Concentration
Page 8Issue No: 1 Issue Date: 29/03/2017
Exc.
8
3
All Methods
Abbott Architect Chemiluminescence
N Mean CV% U SDPA
356 103.919 15.8 1.09 7.39
72 121.451 6.3 1.12 8.64
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
125.950 0.52
0.26
121.451 100
97
Ferritin, ng/ml
%DEV
RM%DEV
3.7
1.9
m
< 60.88 73.18 85.47 97.77 110.06 122.36 134.65 146.95 >
0
10
20
30
40
50
60
70
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
124.6
20
M
111.5
70
M
406.2
78
M
16.0
10
M
253.3
50
M
68.0
15
M
209.6
97
M
406.9
77
M
212.2
54
M
16.2
22
M
253.5
28
M
67.7
07
M
111.2
38
M
212.2
97
M
121.8
67
M
266.9
63
M
18.9
19
M
73.0
36
M
416.2
36
M
121.4
51
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 11.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
16.9%
11.70%RIQAS
Method N Mean CV% U
Roche Modular E170 / Cobas e601/e602 86 111.664 4.1 0.61
Abbott Architect Chemiluminescence 72 121.451 6.3 1.12
Roche Elecsys / Cobas e411 41 108.785 4.7 0.99
Siemens Centaur XP/XPT/Classic 35 100.096 4.1 0.87
Beckman DxI 600 /800 29 74.139 3.7 0.64
Ortho Vitros 3600/5600/ECi 19 71.701 6.1 1.26
Roche Cobas C501/502/701 10 99.568 9.7 3.82
Beckman Access/LXi725 9 74.676 4.6 1.44
Roche Cobas 4000/c311 8 108.928 5.5 2.64
Siemens/DPC Immulite 2000/2500 5 94.820 1.5 0.80
bioMerieux, VIDAS 6 89.017 7.6 3.43
Siemens/DPC Immulite 1000 5 88.540 6.3 3.13
Beckman AU400/600/640/2700/5400 3 94.000 4.9 3.31
Siemens Centaur CP 3 86.667 17.7 11.05
Siemens Dimension 3 100.850 3.6 2.65
DiaSorin, Liaison 2 107.750 2.3 2.19
Monobind Inc. ELISA 1 80.000 0.0 0.00
Tosoh 2 70.450 17.0 10.56
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 50 100 150 200 250 300 350 400
Concentration
Page 9Issue No: 1 Issue Date: 29/03/2017
Exc.
9
0
All Methods
Abbott Architect
N Mean CV% U SDPA
219 5.951 16.5 0.08 0.75
52 5.613 8.3 0.08 0.70
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
5.000 -0.87
-0.07
5.613 78
86
Folate, ng/ml
%DEV
RM%DEV
-10.9
-1.1
m
< 3.38 4.11 4.84 5.58 6.31 7.05 7.78 8.52 >
0
5
10
15
20
25
30
35
40
45
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
8.6
71
M
21.4
04
M
9.2
18
M
1.8
79
M
7.0
22
M
3.4
00
M
5.1
29
M
9.1
07
M
5.1
10
M
1.9
04
M
7.1
57
M
3.4
70
M
23.3
79
M
4.5
36
M
5.4
66
M
6.6
40
M
1.7
57
M
3.4
17
M
8.1
68
M
5.6
13
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 20.6%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
39%
20.60%RIQAS
Method N Mean CV% U
Abbott Architect 52 5.613 8.3 0.08
Roche Cobas 6000/8000 Folate III 32 6.159 6.2 0.08
Siemens Centaur XP/XPT/Classic(enhanced) 28 11.656 11.2 0.31
Beckman DxI 600 /800 - A98032 23 6.679 7.1 0.12
Roche Folate III - 07559992 16 6.024 3.7 0.07
Siemens/DPC Immulite 2000 13 4.900 5.1 0.09
Roche Cobas 4000/e411 Folate III 13 5.560 10.4 0.20
Roche Cobas 4000/e411 10 5.870 6.9 0.16
Roche Cobas 6000/8000 11 6.347 11.9 0.28
Ortho Vitros 3600/5600/ECi 9 3.830 14.8 0.24
Beckman DxI 600 /800 - A14208 7 6.654 5.7 0.18
Beckman Access/LXi725 4 6.612 3.1 0.13
Roche Folate III - 04476433 3 7.971 9.0 0.52
Roche Modular E170 2 6.755 9.3 0.56
Roche Elecsys 2 5.440 14.8 0.71
Roche Modular E170 Folate III 2 6.371 12.9 0.73
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-30
-20
-10
0
10
20
30
Sample Number
% D
evia
tion
>=
<=
-30
-20
-10
0
10
20
30
% D
evia
tion
>=
<=
0 5 10 15 20
Concentration
Page 10Issue No: 1 Issue Date: 29/03/2017
Exc.
30
4
All Methods
Abbott Architect
N Mean CV% U SDPA
375 25.066 10.0 0.16 1.48
76 22.844 4.3 0.14 1.35
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
24.220 1.02
0.18
22.844 71
100
FSH, mU/ml
%DEV
RM%DEV
6.0
1.2
m
< 18.49 20.37 22.25 24.12 26.00 27.88 29.75 31.63 >
0
10
20
30
40
50
60
70
mU/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
24.7
98
M
24.2
89
M
55.7
81
M
5.2
92
M
40.3
18
M
15.2
07
M
30.5
64
M
55.4
41
M
30.2
70
M
5.2
61
M
39.5
07
M
15.2
37
M
24.5
15
M
22.7
17
M
22.9
71
M
32.2
14
M
4.2
36
M
13.8
76
M
41.4
23
M
22.8
44
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 9.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
21.19%
9.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 84 24.569 3.5 0.12
Abbott Architect 76 22.844 4.3 0.14
Roche Cobas 4000/e411 63 25.598 4.3 0.17
Siemens Centaur XP/XPT/Classic 31 30.353 5.3 0.36
Beckman DxI 600 /800 28 28.129 5.8 0.39
Ortho Vitros 3600/5600/ECi 16 20.594 2.5 0.16
bioMerieux, VIDAS 12 30.255 2.9 0.32
Siemens/DPC Immulite 2000/2500 14 24.793 3.8 0.31
Roche Elecsys 10 24.536 4.5 0.44
Siemens/DPC Immulite 1000 7 25.471 6.5 0.78
Roche Modular E170 7 25.193 4.9 0.58
Beckman Access/LXi725 6 28.142 6.3 0.90
DiaSorin Liaison 6 41.150 17.9 3.75
SNIBE Maglumi analysers 5 30.756 16.2 2.78
Tosoh 3 32.500 14.4 3.38
Human ELISA 2 27.900 7.1 1.75
Monobind Inc. ELISA/CLIA 2 22.380 13.4 2.65
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 10 20 30 40 50
Concentration
Page 11Issue No: 1 Issue Date: 29/03/2017
Exc.
26
4
All Methods
Abbott Architect
N Mean CV% U SDPA
541 22.110 11.6 0.14 1.42
99 19.440 5.9 0.14 1.25
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
19.380 -0.05
-0.48
19.440 120
99
hCG, mU/ml
%DEV
RM%DEV
-0.3
-3.1
m
< 15.36 17.28 19.21 21.14 23.07 25.00 26.93 28.85 >
0
20
40
60
80
100
120
mU/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
21.5
39
M
15.4
58
M
337.9
60
M
17.6
54
M
167.3
99
M
15.3
86
M
178.0
28
M
340.6
20
M
177.9
43
M
17.8
55
M
167.3
21
M
15.6
10
M
15.5
56
M
160.7
52
M
19.7
60
M
161.5
03
M
12.9
54
M
16.1
19
M
311.1
61
M
19.4
40
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.6%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
N/A
10.60%RIQAS
Method N Mean CV% U
Roche hCG+Beta 223 22.036 4.5 0.08
Abbott Architect 99 19.440 5.9 0.14
Roche hCG STAT(Intact) 42 22.321 4.4 0.19
Siemens Centaur XP/XPT/Classic 36 23.550 5.2 0.25
Ortho Vitros 3600/5600/ECi 25 31.863 4.0 0.31
bioMerieux, VIDAS / mini VIDAS 22 29.335 10.1 0.79
Beckman DxI 600 /800 16 23.323 3.2 0.23
Siemens/DPC Immulite 2000 14 38.304 11.1 1.42
Beckman DXI Total BhCG (5th IS) 12 22.603 4.5 0.37
Siemens/DPC Immulite 1000 10 36.530 6.6 0.95
Roche Cobas Core EIA 9 22.153 4.9 0.46
Beckman Access Total BhCG (5th IS) 8 22.628 4.6 0.46
Siemens Centaur CP 5 21.080 15.5 1.83
Siemens Dimension 6 29.205 2.7 0.40
Beckman Access/LXi725 6 22.653 4.4 0.51
Radiometer AQT90 Flex 5 21.000 4.8 0.56
DiaSorin, Liaison 5 21.442 17.8 2.13
SNIBE Maglumi analysers 2 22.940 4.6 0.92
ELISA 1 15.550 0.0 0.00
Tosoh 2 37.500 34.3 11.37
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 50 100 150 200 250 300
Concentration
Page 12Issue No: 1 Issue Date: 29/03/2017
Exc.
60
11
All Methods
Abbott Architect
N Mean CV% U SDPA
138 5.133 17.1 0.09 0.45
34 5.827 5.6 0.07 0.51
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
6.000 0.34
-0.69
5.827 119
93
Insulin, uU/ml
%DEV
RM%DEV
3.0
-6.3
m
< 2.82 3.48 4.14 4.80 5.46 6.12 6.78 7.44 >
0
5
10
15
20
25
uU/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
9.2
14
M
6.3
63
M
19.7
50
M
0.7
97
M
12.5
83
M
3.9
96
M
10.5
99
M
19.7
63
M
10.5
81
M
0.8
39
M
12.7
33
M
3.9
88
M
6.3
41
M
14.0
52
M
5.8
28
M
15.8
49
M
1.3
82
M
3.8
55
M
25.9
96
M
5.8
27
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 14.4%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
32.9%
14.40%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 40 4.859 6.3 0.06
Abbott Architect 34 5.827 5.6 0.07
Roche Cobas 4000/e411 23 4.649 6.0 0.07
Siemens Centaur XP/XPT/Classic 10 8.635 3.4 0.11
Siemens/DPC Immulite 2000 7 2.299 16.6 0.18
Beckman DXI 600 / 800 8 5.838 7.4 0.19
Roche Modular E170 5 4.783 3.4 0.09
Siemens/DPC Immulite 1000 4 2.787 14.5 0.25
Roche Elecsys 4 4.855 6.8 0.21
DiaSorin, Liaison 2 5.350 9.3 0.44
Beckman Access/LXi725 3 6.583 3.7 0.18
SNIBE Maglumi analysers 2 6.593 3.3 0.19
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-20
-15
-10
-5
0
5
10
15
20
Sample Number
% D
evia
tion
>=
<=
-20
-15
-10
-5
0
5
10
15
20
% D
evia
tion
>=
<=
0 5 10 15 20 25
Concentration
Page 13Issue No: 1 Issue Date: 29/03/2017
Exc.
21
1
All Methods
Abbott Architect
N Mean CV% U SDPA
368 27.801 14.7 0.27 1.76
72 23.183 5.9 0.20 1.47
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
23.740 0.38
-0.04
23.183 114
99
LH, mU/ml
%DEV
RM%DEV
2.4
-0.3
m
< 17.05 20.12 23.19 26.26 29.33 32.40 35.47 38.54 >
0
10
20
30
40
50
60
70
80
90
mU/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
24.3
26
M
24.7
07
M
54.6
89
M
2.2
47
M
38.3
21
M
13.0
43
M
28.1
88
M
53.1
23
M
27.9
95
M
2.2
27
M
37.4
82
M
12.8
78
M
23.7
84
M
20.3
56
M
23.3
14
M
31.0
44
M
2.2
77
M
13.2
71
M
38.4
65
M
23.1
83
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.4%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
27.92%
10.40%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 86 30.325 3.7 0.15
Abbott Architect 72 23.183 5.9 0.20
Roche Cobas 4000/e411 66 30.287 3.9 0.18
Siemens Centaur XP/XPT/Classic 28 28.235 4.2 0.28
Beckman DXI 600 / 800 27 22.486 4.3 0.23
Ortho Vitros 3600/5600/ECi 16 38.618 4.8 0.57
bioMerieux, VIDAS 15 25.846 7.0 0.59
Siemens/DPC Immulite 2000 15 40.974 6.2 0.82
Roche Elecsys 8 30.316 4.0 0.53
Siemens/DPC Immulite 1000 7 39.843 9.2 1.74
Roche Modular E170 8 29.783 3.5 0.46
Beckman Access/LXi725 7 24.131 5.7 0.65
DiaSorin, Liaison 5 36.538 10.4 2.12
SNIBE Maglumi analysers 4 29.818 17.3 3.22
Monobind Inc. ELISA/CLIA 2 25.150 15.5 3.44
Tosoh 2 33.800 15.5 4.62
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 10 20 30 40 50
Concentration
Page 14Issue No: 1 Issue Date: 29/03/2017
Exc.
27
6
All Methods
Abbott Architect
N Mean CV% U SDPA
324 206.573 17.9 2.57 16.45
62 178.401 3.8 1.07 14.21
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
173.900 -0.32
0.31
178.401 120
104
Oestradiol, pg/ml
%DEV
RM%DEV
-2.5
2.6
m
< 109.25 137.06 164.86 192.67 220.47 248.27 276.08 303.88 >
0
20
40
60
80
100
pg/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
176.6
55
M
170.4
88
M
271.4
67
M
50.8
64
M
219.8
04
M
116.4
98
M
177.2
07
M
269.9
18
M
176.5
28
M
50.9
51
M
220.6
00
M
114.5
71
M
169.6
00
M
170.1
17
M
177.6
50
M
219.3
11
M
61.0
10
M
124.4
78
M
262.2
48
M
178.4
01
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 13.1%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
26.86%
13.10%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 (Estradiol III) 62 189.368 3.9 1.17
Abbott Architect 62 178.401 3.8 1.07
Roche Cobas 4000/e411 (Estradiol III) 43 188.610 6.4 2.28
Beckman DXI 600 / 800 30 256.431 8.7 5.07
Roche Cobas 4000/e411 (Estradiol II) 19 187.213 5.6 2.99
Siemens Centaur XP/XPT/Classic (eE2) 16 262.719 3.6 2.99
bioMerieux, VIDAS 14 305.046 6.2 6.30
Roche Cobas 6000/8000 Estradiol II 12 191.302 1.7 1.20
Siemens/DPC Immulite 2000/2500 11 281.989 4.7 5.02
Ortho Vitros 3600/5600/ECi 10 260.748 4.3 4.44
Roche Elecsys (Estradiol II) 8 181.172 5.7 4.57
Beckman Access/LXi725 7 263.891 7.4 9.28
Roche Elecsys (Estradiol III) 7 190.430 3.5 3.11
Siemens Centaur XP/XPT/Classic 5 261.932 5.0 7.32
Roche Modular E170 (Estradiol III) 5 185.729 3.6 3.79
Siemens/DPC Immulite 1000 4 287.592 6.2 11.07
Diasorin LIAISON 3 164.000 17.1 20.25
Roche Modular E170 (Estradiol II) 2 192.036 8.7 14.71
SNIBE Maglumi analysers 1 357.080 0.0 0.00
Tosoh (E2) 2 218.000 16.2 31.25
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
20 70 120 170 220 270
Concentration
Page 15Issue No: 1 Issue Date: 29/03/2017
Exc.
22
4
All Methods
Abbott Architect
N Mean CV% U SDPA
311 10.538 10.7 0.08 0.88
53 9.614 5.8 0.09 0.80
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
9.700 0.11
0.04
9.614 120
101
Progesterone, ng/ml
%DEV
RM%DEV
0.9
0.3
m
< 7.58 8.43 9.27 10.11 10.95 11.80 12.64 13.48 >
0
10
20
30
40
50
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
7.6
45
M
8.3
15
M
33.2
97
M
0.9
87
M
19.1
38
M
5.2
35
M
17.0
13
M
32.7
67
M
16.6
81
M
0.9
78
M
18.8
32
M
5.2
94
M
8.2
07
M
15.0
72
M
9.5
41
M
18.8
26
M
1.0
86
M
5.5
59
M
29.7
04
M
9.6
14
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 13.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
N/A
13.70%RIQAS
Method N Mean CV% U
Abbott Architect 53 9.614 5.8 0.09
Roche Cobas 4000/e411 (Prog. II) 42 11.204 5.4 0.12
Roche Cobas 6000/8000 (Prog. II) 41 11.188 6.5 0.14
Roche Cobas 6000/8000 (Prog. III) 29 10.655 4.8 0.12
Siemens Centaur XP/XPT/Classic 26 8.924 7.2 0.16
Roche Cobas 4000/e411 (Prog. III) 20 10.767 4.3 0.13
Siemens/DPC Immulite 2000/2500 16 9.443 4.5 0.13
bioMerieux, VIDAS 14 13.686 4.9 0.22
Beckman DXI Prog. Cal 33555 16 11.550 7.3 0.26
Siemens/DPC Immulite 1000 10 9.531 7.1 0.27
Beckman DXI Prog.DE Cal. A80773 11 9.233 7.5 0.26
Roche Elecsys (Prog. II) 8 11.485 6.6 0.34
Ortho Vitros 3600/5600/ECi 7 11.461 5.6 0.30
Roche Modular E170 (Prog. II) 4 11.116 1.6 0.11
Roche Modular E170 (Prog. III) 4 10.977 3.3 0.23
Beckman Access Prog. Cal 33555 4 12.886 8.4 0.68
Diasorin Liaison 3 9.160 7.5 0.50
Beckman Access Prog.DE Cal. A80773 2 10.666 7.9 0.74
SNIBE Maglumi analysers 2 18.410 10.7 1.74
Tosoh 2 14.595 19.4 2.51
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-20
-15
-10
-5
0
5
10
15
20
Sample Number
% D
evia
tion
>=
<=
-20
-15
-10
-5
0
5
10
15
20
% D
evia
tion
>=
<=
0 5 10 15 20 25 30
Concentration
Page 16Issue No: 1 Issue Date: 29/03/2017
Exc.
26
4
All Methods
Abbott Architect
N Mean CV% U SDPA
375 709.488 7.7 3.54 54.78
46 752.379 6.1 8.43 58.09
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
746.130 -0.11
0.11
752.379 120
113
Prolactin, mU/l
%DEV
RM%DEV
-0.8
0.9
m
< 565.54 606.67 647.79 688.92 730.05 771.17 812.30 853.42 >
0
10
20
30
40
50
60
mU/l
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
1746.3
37
M
814.4
64
M
1267.3
65
M
147.6
37
M
1030.8
56
M
479.7
13
M
699.0
36
M
1260.2
80
M
705.8
86
M
146.7
02
M
1029.9
05
M
480.7
92
M
812.7
29
M
750.5
82
M
759.0
83
M
1010.2
39
M
173.9
26
M
464.7
74
M
1295.1
27
M
752.3
79
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 12.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
29.4%
12.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 75 721.394 2.9 3.03
Roche Cobas 4000/e411 64 734.083 4.3 4.92
Abbott Architect 46 752.379 6.1 8.43
Siemens Centaur XP/XPT/Classic 32 632.530 5.2 7.28
Beckman DXI 600 / 800 28 639.319 3.1 4.74
Abbott Architect (Re-standardised) 20 722.878 5.2 10.48
bioMerieux, VIDAS 13 816.722 4.5 12.65
Roche Elecsys/E170/Cobas 6000/8000 PRLII 17 714.688 3.7 7.97
Ortho Vitros 3600/5600/ECi 13 642.159 4.0 8.99
Siemens/DPC Immulite 2000/2500 11 667.810 3.6 8.94
Siemens/DPC Immulite 1000 9 731.751 4.9 14.81
Roche Elecsys 7 716.745 9.9 33.66
Beckman Access/LXi725 8 665.053 7.0 20.52
DiaSorin, Liaison 5 775.440 3.5 15.32
Roche Modular E170 4 710.674 1.5 6.75
Monobind Inc. ELISA/CLIA 4 849.449 13.4 71.17
SNIBE Maglumi analysers 2 753.300 6.3 41.69
Tosoh 3 822.369 23.8 141.54
Siemens Centaur CP 1 514.000 0.0 0.00
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 200 400 600 800 1000 1200 1400 1600 1800
Concentration
Page 17Issue No: 1 Issue Date: 29/03/2017
Exc.
49
6
All Methods
Abbott Architect
N Mean CV% U SDPA
150 11.156 7.5 0.09 0.60
38 11.244 5.7 0.13 0.61
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
11.266 0.04
-0.09
11.244 120
104
PSA, Free, ng/ml
%DEV
RM%DEV
0.2
-0.6
m
< 8.95 9.58 10.21 10.84 11.47 12.09 12.72 13.35 >
0
5
10
15
20
25
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
8.9
09
M
10.7
40
M
25.0
09
M
1.1
34
M
16.5
91
M
5.3
95
M
13.0
96
M
25.6
35
M
12.8
57
M
1.1
46
M
17.1
35
M
5.5
51
M
11.0
86
M
13.6
80
M
11.1
57
M
19.2
03
M
1.3
64
M
6.3
78
M
27.0
42
M
11.2
44
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 8.9%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
N/A
8.90%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 49 11.066 3.8 0.07
Abbott Architect 38 11.244 5.7 0.13
Roche Cobas 4000/e411 27 11.520 5.1 0.14
Siemens Centaur XP/XPT/Classic 12 11.742 9.7 0.41
Beckman DXI standardised to Hybritech 10 15.000 5.3 0.32
Siemens/DPC Immulite 2000/2500 6 9.409 6.4 0.31
Beckman Access standardised to Hybritech 4 14.755 4.6 0.42
DiaSorin, Liaison 3 5.187 4.4 0.17
Roche Modular E170 3 10.830 2.5 0.20
Ortho Vitros 3600/5600/ECi PSA II 3 10.140 1.9 0.14
Roche Elecsys 2 9.920 17.8 1.56
Beckman Access standard to WHO IRP96/670 2 14.580 1.2 0.15
SNIBE Maglumi analysers 2 9.423 8.3 0.69
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-10
-8
-6
-4
-2
0
2
4
6
8
10
Sample Number
% D
evia
tion
>=
<=
-10
-8
-6
-4
-2
0
2
4
6
8
10
% D
evia
tion
>=
<=
0 5 10 15 20 25
Concentration
Page 18Issue No: 1 Issue Date: 29/03/2017
Exc.
26
3
All Methods
Abbott Architect
N Mean CV% U SDPA
490 14.988 14.0 0.12 0.93
91 13.467 5.7 0.10 0.84
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
13.930 0.55
0.19
13.467 97
103
PSA, Total, ng/ml
%DEV
RM%DEV
3.4
1.2
m
< 9.49 11.06 12.63 14.20 15.77 17.34 18.91 20.48 >
0
10
20
30
40
50
60
70
80
90
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
12.7
03
M
13.0
63
M
28.4
66
M
1.5
02
M
20.1
53
M
7.1
28
M
15.4
76
M
28.5
97
M
15.4
72
M
1.5
19
M
20.3
46
M
7.1
05
M
13.2
96
M
16.5
73
M
13.6
62
M
22.2
23
M
1.8
61
M
7.9
45
M
30.9
42
M
13.4
67
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.2%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
33.6%
10.20%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 113 16.449 3.4 0.07
Abbott Architect 91 13.467 5.7 0.10
Roche Cobas 4000/e411 84 17.306 5.0 0.12
Siemens Centaur XP/XPT/Classic 39 12.846 4.8 0.12
Ortho Vitros 3600/5600/ECi PSA II 23 16.417 4.7 0.20
Beckman DXI standardised to Hybritech 18 13.879 4.5 0.18
Siemens Immulite 1000, Total PSA 13 10.480 4.0 0.15
Beckman Access standardised to Hybritech 15 14.063 5.4 0.25
bioMerieux, Vidas TPSA 11 13.488 5.8 0.29
Siemens Immulite 2000/2500, Total PSA 12 11.083 3.7 0.15
Beckman DXI standard to WHO IRP96/670 11 10.468 4.0 0.16
Siemens Centaur CP 8 12.585 16.6 0.92
Roche Elecsys 7 16.497 3.5 0.27
Monobind Inc. ELISA / CLIA 7 19.340 21.7 1.99
Roche Modular E170 7 16.211 6.3 0.48
Ortho Vitros 3600/5600/ECi 5 16.320 4.1 0.37
DiaSorin, Liaison 4 5.938 7.0 0.26
SNIBE Maglumi analysers 4 15.825 12.5 1.24
Beckman Access standard to WHO IRP96/670 3 15.093 7.4 0.80
Tosoh 3 9.370 13.1 0.88
Siemens Immulite 1000, 3rd gen 2 10.095 8.5 0.76
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 5 10 15 20 25 30
Concentration
Page 19Issue No: 1 Issue Date: 29/03/2017
Exc.
31
5
All Methods
Abbott Architect
N Mean CV% U SDPA
184 415.950 23.3 8.95 97.12
31 552.981 12.1 15.02 66.92
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
494.800 -0.87
-0.14
552.981 N/A
N/A
Parathyroid hormone, pg/ml
%DEV
RM%DEV
-10.5
-2.2
m
< 161.02 233.85 306.69 379.53 452.36 525.20 598.04 670.87 >
0
5
10
15
20
25
30
35
40
pg/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
145.6
74
M
560.3
44
M
1552.0
47
M
184.4
91
M
984.9
45
M
449.0
51
M
838.7
77
M
1508.4
10
M
852.3
77
M
195.3
34
M
1042.2
30
M
431.7
46
M
537.9
98
M
488.2
65
M
554.6
71
M
975.5
00
M
31.5
77
M
253.3
56
M
1402.5
53
M
552.9
81
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
30.2%
N/A RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 PTH/PTH STAT 42 371.269 9.2 6.57
Abbott Architect 31 552.981 12.1 15.02
Roche Cobas 4000/e411 PTH/PTH STAT 19 370.933 9.2 9.82
Beckman DXI 600 / 800 19 397.768 6.9 7.91
Roche Cobas 6000/8000 PTH (1-84) 18 338.864 17.1 17.11
Siemens Centaur XP/XPT/Classic 11 567.385 8.8 18.92
Siemens/DPC Immulite 2000 12 670.044 10.4 25.13
Roche Cobas 4000/e411 PTH (1-84) 11 336.552 27.6 35.03
Ortho Vitros 3600/5600/ECi 4 495.275 2.7 8.32
Roche Modular E170 PTH/PTH STAT 4 357.229 5.5 12.20
DiaSorin, Liaison 1-84 PTH 2 376.867 44.0 146.42
DiaSorin, Liaison N-TACT PTH II 2 397.000 64.5 226.25
Beckman Access/LXi725 2 373.450 11.7 38.69
SNIBE Maglumi analysers 2 438.335 51.2 198.33
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 200 400 600 800 1000 1200 1400
Concentration
Page 20Issue No: 1 Issue Date: 29/03/2017
Exc.
17
2
All Methods
Abbott Architect
N Mean CV% U SDPA
345 9.037 13.7 0.08 0.58
67 7.834 7.8 0.09 0.50
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
7.420 -0.83
-0.72
7.834 80
87
Free T3, pg/ml
%DEV
RM%DEV
-5.3
-4.9
m
< 5.79 6.72 7.64 8.57 9.49 10.42 11.35 12.27 >
0
10
20
30
40
50
60
70
pg/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
8.9
88
M
8.5
37
M
15.9
28
M
2.3
37
M
11.5
22
M
4.8
04
M
8.6
98
M
16.2
33
M
8.7
37
M
2.3
88
M
11.6
34
M
5.0
13
M
8.4
92
M
8.3
08
M
7.7
33
M
11.3
78
M
2.2
61
M
4.9
84
M
15.6
89
M
7.8
34
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.5%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
11.3%
10.50%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 84 9.979 2.6 0.04
Abbott Architect 67 7.834 7.8 0.09
Roche Cobas 4000/e411 62 10.046 3.0 0.05
Siemens Centaur XP/XPT/Classic 36 8.690 3.0 0.05
Beckman DXI 600 / 800 23 6.954 6.5 0.12
Ortho Vitros 3600/5600/ECi 13 21.842 2.4 0.18
BioMerieux VIDAS 10 9.308 10.0 0.37
Roche Elecsys 11 9.962 5.7 0.21
Siemens/DPC Immulite 2000/2500 6 6.481 2.0 0.07
Beckman Access/LXi725 9 7.721 7.9 0.26
Roche Modular E170 5 9.683 3.5 0.19
Siemens Centaur CP 4 8.433 4.1 0.22
Siemens/DPC Immulite 1000 4 6.728 8.9 0.38
SNIBE Maglumi analysers 4 6.589 8.0 0.33
DiaSorin Liaison 3 12.067 7.9 0.68
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 2 4 6 8 10 12 14 16
Concentration
Page 21Issue No: 1 Issue Date: 29/03/2017
Exc.
25
2
All Methods
Abbott Architect
N Mean CV% U SDPA
203 256.356 10.7 2.40 19.79
38 223.791 5.2 2.34 17.27
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
209.100 -0.85
-0.26
223.791 79
85
Total T3, ng/dl
%DEV
RM%DEV
-6.6
-2.2
m
< 184.38 204.95 225.51 246.07 266.63 287.19 307.76 328.32 >
0
5
10
15
20
25
30
ng/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
259.7
77
M
236.2
27
M
343.3
65
M
68.0
33
M
290.3
94
M
148.7
77
M
229.9
13
M
352.4
11
M
230.4
32
M
67.7
12
M
292.2
26
M
148.6
26
M
234.3
51
M
217.3
52
M
223.6
54
M
286.6
33
M
59.7
08
M
143.4
06
M
341.7
51
M
223.7
91
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 12.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
9.22%
12.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 45 264.846 3.4 1.69
Abbott Architect 38 223.791 5.2 2.34
Roche Cobas 4000/e411 34 268.218 10.1 5.80
Siemens Centaur XP/XPT/Classic 17 286.283 5.2 4.53
bioMerieux, VIDAS 15 267.993 9.5 8.25
Ortho Vitros 3600/5600/ECi 10 286.212 3.7 4.13
Siemens/DPC Immulite 2000/2500 8 241.743 3.8 4.03
Siemens/DPC Immulite 1000 8 247.664 12.5 13.66
Monobind Inc. ELISA / CLIA 4 283.458 7.6 13.45
Beckman Access/LXi725 5 216.321 1.9 2.32
Beckman DXI 600 / 800 4 225.114 6.2 8.77
Roche Modular E170 3 253.557 2.7 4.90
SNIBE Maglumi analysers 3 291.288 16.8 35.31
Siemens Centaur CP 2 249.351 0.0 0.00
ELISA 2 198.353 34.9 61.25
DiaSorin, Liaison 2 228.500 13.9 28.12
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
20 70 120 170 220 270 320 370
Concentration
Page 22Issue No: 1 Issue Date: 29/03/2017
Exc.
15
3
All Methods
Abbott Architect
N Mean CV% U SDPA
567 3.014 17.2 0.03 0.19
104 2.326 5.3 0.02 0.14
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
2.220 -0.74
-0.25
2.326 85
86
Free T4, ng/dl
%DEV
RM%DEV
-4.6
-1.6
m
< 1.65 2.04 2.43 2.81 3.20 3.59 3.98 4.37 >
0
20
40
60
80
100
120
140
ng/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
2.3
39
M
2.5
15
M
3.9
69
M
0.7
61
M
2.8
73
M
1.4
30
M
2.2
21
M
3.7
63
M
2.1
92
M
0.7
57
M
2.7
79
M
1.4
44
M
2.4
23
M
2.3
97
M
2.2
91
M
2.9
89
M
0.8
55
M
1.6
87
M
3.6
97
M
2.3
26
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 10.2%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
8%
10.20%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 132 3.381 2.9 0.01
Abbott Architect 104 2.326 5.3 0.02
Roche Cobas 4000/e411 100 3.407 3.4 0.01
Siemens Centaur XP/XPT/Classic 52 2.307 4.8 0.02
Beckman DXI 600 / 800 39 3.050 4.1 0.02
Ortho Vitros 3600/5600/ECi 23 6.412 2.8 0.05
Siemens/DPC Immulite 1000 15 3.514 3.8 0.04
Beckman Access/LXi725 16 2.911 5.0 0.05
Siemens/DPC Immulite 2000/2500 15 3.371 2.6 0.03
bioMerieux, VIDAS-FT4N Kit 11 3.883 10.8 0.16
Roche Elecsys 12 3.443 4.7 0.06
Siemens Centaur CP 10 2.615 5.8 0.06
DiaSorin, Liaison 7 4.152 7.3 0.14
Roche Modular E170 6 3.385 3.1 0.05
Monobind Inc. ELISA / CLIA 5 2.423 14.5 0.20
SNIBE Maglumi analysers 4 2.773 9.7 0.17
ELISA 2 2.413 15.4 0.33
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Concentration
Page 23Issue No: 1 Issue Date: 29/03/2017
Exc.
35
10
All Methods
Abbott Architect
N Mean CV% U SDPA
205 10.925 9.1 0.09 0.82
39 10.532 5.7 0.12 0.79
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
10.400 -0.17
0.37
10.532 120
107
Total T4, ug/dl
%DEV
RM%DEV
-1.3
2.8
m
< 8.32 9.06 9.81 10.55 11.29 12.03 12.78 13.52 >
0
5
10
15
20
25
30
35
ug/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
10.5
41
M
10.7
40
M
16.4
93
M
3.1
53
M
13.0
76
M
6.5
18
M
9.1
94
M
16.2
86
M
9.1
47
M
3.1
33
M
13.0
85
M
6.5
29
M
10.7
16
M
9.7
94
M
10.5
52
M
13.5
56
M
3.2
53
M
7.0
65
M
16.3
18
M
10.5
32
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 12.3%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
7%
12.30%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 46 10.252 3.8 0.07
Abbott Architect 39 10.532 5.7 0.12
Roche Cobas 4000/e411 31 10.823 3.4 0.08
bioMerieux, VIDAS 15 12.920 6.2 0.26
Siemens/DPC Immulite 2000/2500 18 11.861 7.7 0.27
Siemens Centaur XP/XPT/Classic 15 11.935 4.5 0.18
Siemens/DPC Immulite 1000 8 12.440 15.3 0.84
Ortho Vitros 3600/5600/ECi 7 11.976 3.9 0.22
Monobind Inc. ELISA 5 11.338 21.0 1.33
Beckman Access/LXi725 5 11.521 6.4 0.41
Beckman DXI 600 / 800 3 11.629 1.9 0.16
Roche Modular E170 3 10.120 5.1 0.37
SNIBE Maglumi analysers 3 14.611 17.8 1.87
Siemens Centaur CP 2 10.953 14.9 1.44
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 2 4 6 8 10 12 14 16 18
Concentration
Page 24Issue No: 1 Issue Date: 29/03/2017
Exc.
19
1
All Methods
Abbott Architect
N Mean CV% U SDPA
278 441.379 10.6 3.49 38.10
33 424.959 6.0 5.59 36.69
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
429.170 0.11
0.10
424.959 120
96
Testosterone, ng/dl
%DEV
RM%DEV
1.0
1.0
m
< 319.11 354.04 388.98 423.91 458.84 493.77 528.70 563.64 >
0
10
20
30
40
50
ng/dl
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
341.6
27
M
420.0
15
M
912.1
75
M
45.2
81
M
615.5
63
M
205.2
24
M
475.1
76
M
930.2
97
M
474.0
21
M
44.4
86
M
613.4
92
M
199.6
53
M
422.2
16
M
439.5
57
M
429.7
85
M
642.6
24
M
45.8
66
M
242.3
99
M
870.8
50
M
424.9
59
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 14.2%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
13.61%
14.20%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 Test II 68 468.186 4.4 3.13
Roche Cobas 4000/e411 Test II 48 454.160 5.9 4.85
Abbott Architect 33 424.959 6.0 5.59
Beckman DXI 600 / 800 27 382.874 3.6 3.27
Abbott Architect 2nd gen 17 416.317 7.1 8.94
Siemens Centaur XP/XPT/Classic TSTO 17 385.211 12.7 14.83
Siemens/DPC Immulite 2000/2500 15 528.971 9.7 16.50
Roche Elecsys Test II 11 461.139 8.2 14.29
bioMerieux VIDAS Testosterone II 7 346.429 8.0 13.06
Ortho Vitros 3600/5600/ECi 9 553.404 10.2 23.49
Roche Modular E170 Test II 6 474.000 2.9 6.91
Beckman Access/LXi725 5 435.236 5.0 12.22
Siemens Centaur XP/XPT/Classic TSTII 4 405.491 3.0 7.54
Siemens/DPC Immulite 1000 3 692.333 14.2 71.08
Diasorin Liaison 2 201.500 16.5 29.37
bioMerieux VIDAS 2 498.500 60.6 266.87
SNIBE Maglumi analysers 2 567.800 20.5 102.75
TOSOH 2 482.340 18.1 77.07
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-20
-15
-10
-5
0
5
10
15
20
Sample Number
% D
evia
tion
>=
<=
-20
-15
-10
-5
0
5
10
15
20
% D
evia
tion
>=
<=
20 120 220 320 420 520 620 720 820 920
Concentration
Page 25Issue No: 1 Issue Date: 29/03/2017
Exc.
26
4
All Methods
Abbott Architect
N Mean CV% U SDPA
621 2.320 8.6 0.01 0.14
111 2.021 4.2 0.01 0.12
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
1.990 -0.26
0.30
2.021 120
99
TSH, uU/ml
%DEV
RM%DEV
-1.5
1.8
m
< 1.79 1.94 2.09 2.24 2.39 2.54 2.69 2.84 >
0
20
40
60
80
100
120
140
uU/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
2.0
11
M
1.9
89
M
19.0
33
M
0.1
39
M
7.1
87
M
1.2
04
M
6.5
57
M
18.8
61
M
6.5
17
M
0.1
38
M
7.1
74
M
1.2
04
M
1.9
75
M
6.6
11
M
2.0
41
M
7.2
83
M
0.1
26
M
1.1
28
M
17.5
20
M
2.0
21
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 9.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
23.7%
9.70%RIQAS
Method N Mean CV% U
Roche Cobas 6000/8000 136 2.426 2.4 0.01
Roche Cobas 4000/e411 115 2.423 3.3 0.01
Abbott Architect 111 2.021 4.2 0.01
Siemens Centaur XP/Classic TSH3-Ultra 30 2.343 2.8 0.02
Ortho Vitros 3600/5600/ECi 27 2.690 5.4 0.03
Siemens Centaur XP/XPT/Classic 23 2.383 5.2 0.03
bioMerieux VIDAS TSH 21 2.454 5.7 0.04
Access/LXi725 hyper TSH 3rd gen. 18 2.104 5.0 0.03
Beckman DXI600/800 Access(3rd IS) 18 2.047 3.8 0.02
Siemens/DPC Immulite 1000 17 2.452 4.7 0.04
Siemens/DPC Immulite 2000/2500 16 2.401 5.5 0.04
Beckman DXI 600 / 800 Hyper TSH 14 2.141 7.9 0.06
Roche Elecsys 12 2.392 3.7 0.03
DiaSorin Liaison 7 2.923 4.2 0.06
Monobind Inc. ELISA / CLIA 7 2.337 19.2 0.21
Roche Modular E170 6 2.372 2.3 0.03
Biomerieux VIDAS TSH3 Ultrasensitive 6 2.279 8.1 0.09
Siemens Centaur CP 6 2.210 12.0 0.14
Access/LXi725 Fast TSH 2nd gen. 5 2.044 4.2 0.05
SNIBE Maglumi analysers 4 2.487 7.4 0.12
Siemens Centaur CP TSH3-Ultra 3 2.256 8.4 0.14
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-15
-10
-5
0
5
10
15
Sample Number
% D
evia
tion
>=
<=
-15
-10
-5
0
5
10
15
% D
evia
tion
>=
<=
0 2 4 6 8 10 12 14 16 18
Concentration
Page 26Issue No: 1 Issue Date: 29/03/2017
Exc.
36
9
All Methods
Abbott Architect
N Mean CV% U SDPA
281 530.097 8.1 3.19 49.63
62 527.708 6.0 5.02 49.41
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
535.000 0.15
-0.20
527.708 120
97
Vitamin B12, pg/ml
%DEV
RM%DEV
1.4
-1.8
m
< 417.85 449.92 481.99 514.06 546.13 578.20 610.26 642.33 >
0
10
20
30
40
50
pg/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
503.6
87
M
567.9
95
M
825.2
50
M
180.2
82
M
937.1
30
M
299.3
38
M
502.0
60
M
852.7
81
M
500.1
50
M
181.1
60
M
956.0
07
M
298.6
87
M
582.0
34
M
521.1
35
M
518.2
67
M
995.8
58
M
189.9
83
M
341.9
60
M
910.4
90
M
527.7
08
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 15.4%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
30%
15.40%RIQAS
Method N Mean CV% U
Abbott Architect 62 527.708 6.0 5.02
Roche Cobas 6000/8000 51 545.061 3.6 3.41
Siemens Centaur XP/XPT/Classic 31 574.138 5.6 7.28
Roche Cobas 4000/e411 33 528.616 9.0 10.40
Beckman DXI 600 / 800 29 444.724 4.6 4.76
Roche Cobas 6000/8000 Gen II 20 546.993 2.8 4.30
Siemens/DPC Immulite 2000 15 480.740 13.5 20.93
Ortho Vitros 3600/5600/ECi 11 558.005 4.7 9.84
Roche Cobas 4000/e411 Gen II 8 538.232 4.6 10.98
Beckman Access/LXi725 7 464.894 6.0 13.28
Roche Modular E170 6 537.254 5.2 14.27
Roche Elecsys 5 496.972 4.8 13.25
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-20
-15
-10
-5
0
5
10
15
20
Sample Number
% D
evia
tion
>=
<=
-20
-15
-10
-5
0
5
10
15
20
% D
evia
tion
>=
<=
90 190 290 390 490 590 690 790 890 990
Concentration
Page 27Issue No: 1 Issue Date: 29/03/2017
Exc.
24
6
All Methods
Abbott Architect
N Mean CV% U SDPA
162 13.588 23.2 0.31 1.79
48 14.504 8.2 0.21 1.91
Your Result SDI
RMSDI
Mean for Comparison TS
RMTS
14.100 -0.21
0.05
14.504 120
110
25-OH-Vitamin D, ng/ml
%DEV
RM%DEV
-2.8
1.0
m
< 5.32 7.68 10.04 12.40 14.76 17.12 19.48 21.84 >
0
5
10
15
20
25
30
ng/ml
Num
ber o
f L
aborato
rie
s
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-1
0
1
Sample Number
Sta
ndar
d D
evia
tion
M
22.4
20
M
19.9
41
M
29.2
09
M
11.1
32
M
25.3
78
M
16.9
54
M
20.5
92
M
29.8
66
M
20.7
12
M
11.0
83
M
26.2
69
M
16.5
95
M
20.4
95
M
21.8
50
M
14.7
01
M
23.0
10
M
9.9
79
M
12.1
10
M
32.0
83
M
14.5
04
<-3
-2
-1
0
+1
+2
>+3
Mean for Comparison
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
110
120
Sample Number
Tar
get
Sco
re
TDPA = 21.7%
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
RIQAS ABC
Acceptable limits derived from Biological Variation
Acceptable limits of performance for
N/A
21.70%RIQAS
Method N Mean CV% U
Roche Vitamin D Total 65 11.133 15.5 0.27
Abbott Architect 48 14.504 8.2 0.21
Siemens Centaur XP/XPT/Classic 13 29.646 4.4 0.45
Beckman DxI 600 /800 12 12.728 12.2 0.56
Diasorin Liaison 10 17.105 8.6 0.58
Ortho Vitros 3600/5600/ECi 7 20.643 12.4 1.21
bioMerieux Vidas/mini Vidas/Vidas 3 5 16.960 8.8 0.84
IDS iSYS 2 19.972 2.4 0.43
Beckman Access 25 OH Vitamin D Total 2 12.179 6.5 0.70
m
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
-30
-20
-10
0
10
20
30
Sample Number
% D
evia
tion
>=
<=
-30
-20
-10
0
10
20
30
% D
evia
tion
>=
<=
0 5 10 15 20 25 30 35
Concentration
Page 28Issue No: 1 Issue Date: 29/03/2017
Exc.
20
4
IMMUNOASSAY LABORATORY REF. NO. 18042/N CYCLE 46 SAMPLE 7 27/03/2017
Analyte
Mean for
Comparison
Your
Result SDI RMSDI %DEV RM%DEV TS RMTS Performance
AFP 67.904 70.140 0.51 0.24 3.3 1.6 101 99
CA 125 141.816 147.200 0.64 0.29 3.8 1.8 91 101
CA 15-3 53.698 55.100 0.40 -0.07 2.6 -0.4 112 109
CA 19-9 705.827 732.280 0.52 0.11 3.7 0.8 100 90
CEA 30.080 29.960 -0.07 0.11 -0.4 0.6 120 102
Cortisol 18.305 19.500 0.86 0.86 6.5 6.4 78 81
DHEA-S 519.313 551.600 0.80 0.22 6.2 1.8 81 101
Ferritin 121.451 125.950 0.52 0.26 3.7 1.9 100 97
Folate 5.613 5.000 -0.87 -0.07 -10.9 -1.1 78 86
FSH 22.844 24.220 1.02 0.18 6.0 1.2 71 100
hCG 19.440 19.380 -0.05 -0.48 -0.3 -3.1 120 99
Insulin 5.827 6.000 0.34 -0.69 3.0 -6.3 119 93
LH 23.183 23.740 0.38 -0.04 2.4 -0.3 114 99
Oestradiol 178.401 173.900 -0.32 0.31 -2.5 2.6 120 104
Progesterone 9.614 9.700 0.11 0.04 0.9 0.3 120 101
Prolactin 752.379 746.130 -0.11 0.11 -0.8 0.9 120 113
PSA, Free 11.244 11.266 0.04 -0.09 0.2 -0.6 120 104
PSA, Total 13.467 13.930 0.55 0.19 3.4 1.2 97 103
Parathyroid hormone 552.981 494.800 -0.87 -0.14 -10.5 -2.2 N/A N/A
Free T3 7.834 7.420 -0.83 -0.72 -5.3 -4.9 80 87
Total T3 223.791 209.100 -0.85 -0.26 -6.6 -2.2 79 85
Free T4 2.326 2.220 -0.74 -0.25 -4.6 -1.6 85 86
Total T4 10.532 10.400 -0.17 0.37 -1.3 2.8 120 107
Testosterone 424.959 429.170 0.11 0.10 1.0 1.0 120 96
TSH 2.021 1.990 -0.26 0.30 -1.5 1.8 120 99
Vitamin B12 527.708 535.000 0.15 -0.20 1.4 -1.8 120 97
25-OH-Vitamin D 14.504 14.100 -0.21 0.05 -2.8 1.0 120 110
ORMSDI 0.03 ORM%DEV 0.1 ORMTS 98
RIQAS ABCPage 29
END OF REPORT
Issue No: 1 Issue Date: 29/03/2017